bioAffinity Technologies, Inc. reported a net revenue of approximately $1.35 million for the three months ended March 31, 2026, a decrease of 27% from $1.85 million in the same period of the previous year. The decline in revenue is attributed to the discontinuation of certain unprofitable pathology services, although this was partially offset by a significant increase in revenue from the CyPath® Lung diagnostic test, which saw a 114% rise to $361,000 compared to $169,000 in the prior year. The company recorded a net loss of approximately $3.63 million for the first quarter of 2026, compared to a net loss of $2.66 million for the same period in 2025.

In terms of operational metrics, bioAffinity's direct costs and expenses decreased by 32% to $928,636, reflecting strategic actions taken in March 2025 to streamline operations. Research and development expenses slightly decreased by 5% to $349,707, while clinical development expenses surged by 141% to $334,040, primarily due to the initiation of a pivotal clinical trial. Selling, general, and administrative expenses increased by 32% to $3.24 million, driven by higher employee compensation and additional personnel to support the growth of CyPath® Lung sales.

The company’s total assets decreased to approximately $7.95 million as of March 31, 2026, down from $10.96 million at the end of 2025. This decline was primarily due to a reduction in cash and cash equivalents, which fell to $3.1 million from $6.4 million. The accumulated deficit increased to approximately $72.2 million, reflecting ongoing operational losses since the company's inception in 2014. The company also reported a working capital of approximately $1.2 million.

Looking ahead, bioAffinity Technologies faces substantial doubt regarding its ability to continue as a going concern for at least the next twelve months, as indicated in its filing. The company plans to raise additional capital through equity or debt securities to support its operations and product development. As of May 4, 2026, the company had cash and cash equivalents of $1.7 million, which is expected to support operations through June 2026. The company is actively seeking financing options to ensure continued development of its diagnostic tests and therapeutic products.

About bioAffinity Technologies, Inc.

bioAffinity Technologies develops noninvasive diagnostic tests for early lung cancer detection using flow cytometry and AI-driven analysis of sputum samples. Its flagship product, CyPath Lung, aims to improve diagnostic accuracy, reduce unnecessary invasive procedures, and support timely treatment. The company also explores therapeutic discoveries and operates a clinical laboratory, serving high-risk populations and healthcare providers worldwide in the growing cancer diagnostics market.

This description was generated via AI from an annual report. Updated 9 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.